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INTRODUCTION: THE NEED FOR BETTER 
IMMUNOSUPPRESSANTS 
Four classes of drugs have been used as immuno-
suppressive agents in human autoimmune 
diseases-corticosteroids, alkylating agents (cyclo-
phosphamide and chlorambucil), antimetabolites 
(azathioprine and methotrexate) and more recently, 
cyclosporin A (CsA). Before the introduction of CsA 
within the last decade, the successful use of immunos-
uppressive drugs in autoimmune disease was restric-
ted to systemic lupus erythematosus (SLE), rheuma-
toid arthritis, myasthenia gravis and nephrotic 
syndrome. esA, which acts selectively to inhibit T 
cell activation and cytokine production has changed 
the situation. Now, using esA, significant improve-
ment in a higher proportion of patients than pre-
viously observed can be achieved in autoimmune dis-
eases with a presumed T cell pathogenesis. These 
include psoriasis, uveitis, insulin-dependent (type I) 
diabetes mellitus, primary biliary cirrhosis, aplastic 
anaemia, lichen planus and severe allergic asthma. 
Autoimmune disorders mediated by autoantibodies 
however, such as the autoimmune cytopenias, myas-
thenia gravis, SLE, Graves' disease and glomerulo-
nephritides are relatively resistant to CsA. In addition 
to the improved rate of response seen with esA, 
opportunistic infections are very rare in CsA-treated 
autoimmune disease patients. Despite the successes 
achieved with esA, however, several problems con-
tinue to exist. These are (1) an insufficient response 
rate, (2) disease recurrence following drug withdrawal 
and (3) the associated risks of drug toxicity or excess-
ive immunosuppression. The most common side 
effects are infections, lymphoproliferative disease, 
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nephrotoxicity including arterial hypertension, cos-
metic deformity with hirsutism and coarsening of the 
facies, hypercholesterolemia and an increased dispo-
sition to diabetes mellitus. These difficulties have 
driven the search for new agents that act with pre-
cision on those components of the immune system 
involved in disease pathogenesis but not on thera-
peutically irrelevant cells. Amongst the most promis-
ing new candidate drugs is FK 506. Already the 
advent of FK 506 and its use as an investigational tool 
has had a major impact on our understanding of mol-
ecular mechanisms underlying T cell activation and at 
a clinical level, on the practice of organ transplan-
tation. Its efficacy in the prevention of allograft rejec-
tion is well documented; more germane to the auto-
immune field is its ability to reverse established 
rejection which is thought to follow the same mechan-
isms as many autoimmune diseases. In this context, 
the rejecting organ graft (or bone marrow) may be 
thought of as a direct analogue of many autoimmune 
disorders. 
FK 506 IN PERSPECTIVE 
The powerful immunosuppressive properties of FK 
506, a fungally-derived macrolide antibiotic, were 
first documented in 1987,,2. Although totally distinct 
in structure from the fungal product and cyclic peptide 
esA, FK 506 shares many of the properties of the lat-
ter drug. The two agents exhibit very similar molecu-
lar actions which inhibit T helper lymphocyte acti-
vation, cytokine production and lymphocyte 
proliferation. FK 506, however, is a considerably 
more potent immunosuppressant than CsA 1-3 and sig-
nificantly, has a superior ability to reverse acute and 
early chronic liver allograft rejection in man4 • A 
closely related structural analogue of FK 506, rapa-
mycin (RAPA), is also an extremely potent inhibitor 
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of T cell responses, although its mode of action is 
quite distinct from that of FK 506 and CsA and affects 
a later stage in the T cell activation-proliferation path-
way (reviewed by Kahan et al.s). Because of a better 
therapeutic margin (before the advent of limiting side 
effects), FK 506 appears to have a greater steroid 
sparing effect than CsA in the management of human 
organ transplant rejection and thus, may be of special 
benefit to children. Infectious complications are no 
greater and may be reduced as a consequence. The 
principal potential side effects of FK 506 (nephro- and 
neurotoxicity and diabetogenicity) are similar to those 
of CsA 6. FK 506, however, does not cause such severe 
elevfltions of blood pressure, gum hyperplasia or hir-
sutism, which are commonly encountered side effects 
of highdose CsA. Single centre studies 7-9 reporting 
improved results with FK 506 in human liver, heart 
and kidney transplantation compared with historical, 
CsA-treated controls, have been followed by multi-
centre, prospective randomized controlled studies of 
FK 506 in primary liver transplantation trials cur-
rently in progress in Europe, the United States and 
Japan. These centres have already confirmed the 
ability of FK 506 to reverse liver allograft rejection in 
up to 50% of patients unresponsive to other therapies. 
Reversal of heart and kidney rejection has also been 
documented 10. It is established that FK 506 is compat-
ible with steroids, azathioprine, and antilymphoid 
agents (such as OKT3), although the increased immu-
nologic nonspecificity of "cocktail" therapy increases 
the risk of infections and neoplastic complications as 
is the case with CsA. In Japan and in Pittsburgh, clini-
cal studies of the efficacy and safety of FK 506 in kid-
ney and bone marrow transplantation are in progress. 
Armed with experience and encouraging results under 
all of these circumstances, preliminary studies of the 
efficacy and safety of FK 506 in human autoimmune 
diseases have begun in the United States and Japan. 
This short review will outline the properties of FK 
506, its molecular action and anti-lymphocytic 
activity and its pharmacokinetic and toxic properties 
in animals and man. The effects of FK 506 in exper-
imental and clinical organ transplantation have been 
reviewed. extensively elsewhere lO- 14. 
The influence of FK 506 in experimental auto-
immune disorders will be reviewed and the limited 
clinical experience with FK 506 in human auto-
immune disease will be examined. 
PHYSICOCHEMICAL PROPERTIES OF FK 506 
FK 506 was discovered by the Fujisawa Pharmaceut-
ical Co., Osaka, Japan, during routine screening of the 
fermentation broths of Streptomyces spp. for specific, 
inhibitory effects on mouse mixed lymphocyte reac-
tions (MLR)I.2,ls. Although classified according to its 
structure (Figure 1) and function as a macrolide anti-
biotic, FK 506 exhibits only limited antifungal 
activity. It is insoluble in water, but dissolves readily 
in non-polar solvents, such as ethanol. The molecular 
formula of FK 506, deduced by elemental analysis and 
mass spectrometry, is C44H69N012'H20 (mw 822 da). It 
is relatively stable under normal laboratory con-
ditions. Reports of its synthesis appeared in 198916.17• 
MODE OF ACTION AT THE CELLULAR AND 
MOLECULAR LEVELS 
There is substantial evidence based on in vitro cell 
culture studies that, like CsA, FK 506 inhibits selec-
tively, CD4+ T lymphocyte activation and cytokine 
production, with consequent inhibitory effects on 
other T and non-T cell components of the immune 
system. Like CsA, FK 506 inhibits T cell activation 
mediated by the T cell antigen receptor (TCR)-CD3 
complex and also via the cell surface molecule CD2. 
It is very effective in suppressing alloantigen or T cell 
mitogen-induced lymphocyte proliferation at concen-
trations 100-fold lower than effective concentrations 
of CsA2.18,19. The drug also inhibits the generation of 
cytotoxic and suppressor T cells in human MLR but 
does not affect antigen recognition by cytotoxic T 
cells or the mechanism by which target cells are 
destroyed20. FK 506 does not appear to inhibit antigen 
processing or presentation by human monocytes at 
drug concentrations which strongly suppress T cell 
proliferation21 . There is also evidence that FK 506 
does not affect directly human natural killer (NK) cell 
activity or antibody dependent cytotoxicity. Interest-
ingly, however, both FK 506 and CsA inhibit pro-
inflammatory mediator release from human baso-
phils22. Thus, the ability of FK 506 to inhibit mediator 
release from basophils and mast cells may contribute 
to some of its therapeutic effects in graft rejection and 
autoimmune disease. 
In T lymphocytes, FK 506 disrupts an unknown 
step in the transmission of signals from the TCR to 
genes that coordinate the immune response. Consider-
able effort has been expended by several laboratories 
to identify the precise target of FK 506 in the T cell 
activation pathway. Experiments designed to ascertain 
the influence of FK 506 on very early events prior to 
gene transcription following binding of the antigen 
receptor have shown that the drug does not affect Ca++ 
mobilization, phosphatidylinositol turnover or protein 
kinase C (PKC) activities. FK 506 does, however, 
strongly and specifically inhibit expression of early T 
cell activation genes encoding interleukin-2 (IL-
2)-the main growth factor for T cells, IL-3, IL-4, 
IFN-y, GM-CSF and c_myc I8 • On the other hand, 
recent studies have shown that FK 506 may spare IL-
10 (cytokine synthesis inhibitory factor=CSIF) gene 
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FK 506 
Effector Element 
Rapamycin 
Effector Element 
transcription by cloned murine T helper-2 (TH2) cells 
in vitro, whilst suppressing concomitant IL-4 mRNA 
production by these cells23 • Thus, differential inter-
ference with T cell cytokine gene expression may be 
an important mechanism whereby FK 506 inhibits 
immune cell activation and immune suppression is 
maintained. 
Clues to the molecular action of FK 506 and CsA 
come from studies of their intracellular receptors, FK 
506 binding protein (FKBP) and cyclophilin, respect-
ively, each of which is a cis-trans peptidyl prolyl 
isomerase(PPIase)16,17,24. Although binding of the drug 
by its receptor (or "immunophilin") inhibits isomerase 
activity, recent results indicate that the immunosup-
pressive effects of FK 506 and CsA result from the 
formation of complexes between the drug and its 
respective isomerase25 . Both the complex of FK 506 
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Figure 1 Structures of the 
immunosuppressive macrolides FK 506 
and Rapamycin showing the FKBP 
binding domain and the effector 
element of each molecule. 
and FKBP and the complex of CsA and cyclophilin 
have been shown to bind specifically to three 
polypeptides-calmodulin and the two subunits of 
calcineurin (a Ca++ -activated, serine-threonine protein 
phosphatase). In each case, the interaction of the 
immunophilin appears to be with calcineurin (Figure 
2). The drug-immunophilin complexes have been 
shown to block the Ca++-activated phosphatase 
activity of calcineurin24• Thus, calcineurin appears to 
be the target of the drug-immunophilin complexes. 
A second, important observation in unravelling the 
molecular action of FK 506 is that the drug-immuno-
philin complexes block Ca++ -dependent translocation 
of the pre-existing, cytoplasmic component of NF-AT 
(nuclear factor of activated T cells) to the nUcleus 26 • 
The nuclear component of NF-AT is transcriptionally 
inactive in all cells other than activated T lympho-
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Figure 2 Within the T lymphocyte, FK 506-FKBP or CsA-
cyclophilin complexes bind with high affinity to calcineurin-
calmodulin to form a pentameric complex which interferes with Ca++-
dependent signalling pathways. Complexes of RAPA-FKBP do not 
bind to calcineurin. Recent observations25 indicate that calcineurin (a 
protein phosphatase) is the target of the FK 506-FKBP and CsA-
cyclophilin complexes. CaM=calmodulin; CNA=calcineurin A; 
CNB=calcineurin B; CYP=cyclophilin; FKBP=FK 506 binding 
protein. 
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Figure 3 Influence of FK 506 on signal transduction within T cells. 
The crucial event in T-cell activation stimulated by antigen plus IL-l 
would appear to be activation of the phospholipase which splits 
phosphatidyl inositol diphosphate into the reactive products 
diacylglycerol and inositol triphosphate. The increased intracellular 
calcium concentration activates a' number of different enzyme 
systems which lead to new synthesis of RNA, protein and IL-2. FK 
506 blocks translocation of the pre-existing cytoplasmic component 
(B) of the nuclear protein NF-AT at the nucleus'" by acting either on 
a CaH signalling pathway or on translocation following the action of 
this pathway (arrows). Both components of NF-AT are required for 
DNA binding and activation of the IL-2 gene. TCR=T cell receptor; 
DAG=diacylglycerol; PLC=phospholipase C, PKC=protein kinase C; 
A=induced nuclear component of NF-AT; B=existing cytoplasmic 
component of NF-AT. 
cytes and is induced by signals from the TCR. Its 
appearance is not blocked by FK 506 or CsA. Current 
thinking is that FK 506 and CsA block dephosphoryl-
---
cell differentiation 
cell proliferation 
Figure 4 Differential effects of the immunosuppressive macrolides 
FK 506 and RAPA on T-cell activation and proliferation. FK 506 
(and CsA) inhibit pre-transcriptional events in CD4+ T cell 
activation, resulting in suppression of production of IL-2 and other 
cytokines. In contrast, RAPA does not impair IL-2 production, lL-2R 
expression or ligand binding to IL-2R but blocks the response of T-
cells to IL-2 and other cytokines (lL-4, IL-6). TCR=T cell receptor; 
LKR=lymphokine receptor. 
ation of the cytoplasmic component of NF-A T which 
is required for its translocation to the nucleus (Figure 
3), In the absence of both nuclear and cytoplasmic 
components, binding of NF-AT to DNA and transcrip-
tional activation of the IL-2 gene is suppressed. The 
molecular action of the immunosuppressive macrolide 
RAPA, which inhibits Ca++-independent signalling 
and which binds to the same cytosolic receptor 
(FKBP) as FK 506 is quite distinct from that of the 
latter drug (see Figures 2 and 4). 
FK 506 MONITORING AND 
PHARMACOKINETICS 
FK 506 may be quantified in body fluids, following 
extraction of the drug, by enzyme-linked immuno-
sorbant assay (ELISA), using either a monoclonal or 
polyclonal antibody. The sensitivity limit for the 
assay described originally by Tamura et al. 27 is 
20 pg/ml FK 506 in plasma. A modified ELISA, in 
which a solid phase extraction method and a mouse 
monoclonal anti-FK 506 antibody are used for quan-
titation of FK 506 in human plasma has recently been 
described 28 • The extent to which the antibody cross-
reacts with FK 506 metabolites is unknown and thus 
plasma levels as determined at present denote native 
molecule plus metabolites. 
In whole blood, FK 506 is highly bound to erythro-
cytes, with a mean blood:plasma trough concentration 
ratio of 10: 1. FK 506 is slowly absorbed after oral 
administration and distributed in various organs, 
including lung, spleen, heart and kidney"9. Unlike 
CsA, the absorption of FK 506 does not appear to be 
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dependent on the availability of bile in the gut. It 
seems that the majority of FK S06 is metabolized by 
N-demethylation and hydroxylation in the liver and is 
then excreted in bile. urine and faeces within 48 hr of 
administration29.1o . In patients with hepatic dysfunc-
tion. the half-life of FK S06 is increased and its clear-
ance reduced, increasing drug bioavailability and thus 
the risk of associated toxicity. 
With intravenous administration, peak FK S06 
plasma concentration in transplant patients is 
observed at the end of infusion. Levels decline slowly 
over the next 24 hr29•30 • Plasma trough levels tend to 
be about 1 ng/ml, but the effective immunosuppress-
ive concentration in vitro may be much lower than 
this. The half-life of FK S06 ranges from 3.S to 
40.S hr, with a mean of 8.7 hr. Drug absorption fol-
lowing oral administration is highly variable with 
mean bioavailability of about 25% (range 6-57%). 
Peak plasma level of 0.4 to 3.7 ng/ml is reached after 
1 to 4 hr of an oral dose at 0.15 mg/kg. 
A number of interactions of FK 506 with other 
drugs has been observed in studies at the University of 
Pittsburgh. Trough plasma concentrations of FK 506 
in man are increased by co-administration of erythro-
mycin, fluconazole and c1otrimazole, whilst the 
effects of phenytoin, phenobarbital and acyclovir on 
FK 506 pharmacokinetics are currently under study. 
TOXICITY 
The toxic effects of FK 506 in experimental animals 
(rodents. rabbits, dogs and primates) have been well 
documented'i. Dogs are susceptible to FK S06 toxicity 
and exhibit dose-related vasculitis and intusussep-
tions. Studies by several groups have shown that the 
toxic effects of FK 506 in non-human primates are 
more pronounced when the drug is administered i.m. 
compared with orally, due presumably, to be greater 
bioavailability achieved using the former route. FK 
506 does not exhibit mutagenic activity in either in 
!'itro or in vivo tests. Fetotoxicity has been demon-
strated in rats and in rabbits, teratogenic effects have 
been observed. 
In humans, adverse reactions requiring treatment or 
dose reduction are impairment of renal function 
(attributable in part to reduced renal blood flow), 
alterations in glucose metabolism (15 % incidence of 
new onset diabetes in transplant patients) and neuro-
toxicity". The reported overall incidence of post-trans-
plant lymphoproliferative disorders in all (936) first 
organ transplant recipients receiving FK 506 as pri-
mary immunosuppressive therapy at the University of 
Pittsburgh Medical Centre is 1.6%32. Although a 200/0 
incidence of CMV infections has been observed in FK 
506-treated transplant patients6 , no patient treated 
with FK S06 for non-transplant indications has devel-
oped CMV infection. These side effects are similar to 
those associated with CsA administration. FK 506 
use, however, has a lower incidence of hypertension 
than CsA, and gum hyperplasia and hirsutism are not 
seen. 
An intriguing issue is whether the nephrotoxic 
potential of FK S06 and CsA correlates with the 
drugs' PPIase inhibitory activities. Recent data33 indi-
cate that immunosuppressive activity and not immun-
ophilin binding or PPIase inhibitory activity deter-
mines the ability of CsA analogues to induce 
nephrotoxicity. It may thus be difficult to design new 
nonnephrotoxic drugs that retain the same potent 
immunosuppressive activity. 
EFFECTS OF FK 506 ON IMMUNE REACTIVITY 
The very potent inhibitory effects of FK 506 on humo-
ral and cell-mediated immune responses were first 
reported by Kino et at. in 1987 1, using mice as exper-
imental models. Subsequent reports have confirmed 
the powerful immunosuppressive properties of FK 
506 in rodents, dogs and primates. These include 
models of organ allograft rejection, ranging from skin 
grafts to multi-visceral transplants (see recent 
reviews3•10- 13). FK 506 is also effective in preventing 
and reversing graft-versus-host disease after exper-
imental bone marrow transplantation. In each 
instance, FK 506 has been shown to be about lO-fold 
more potent than CsA. 
There is little doubt that FK S06-induced immuno-
suppression results from the inhibition of CD4+ T 
helper cell activities. Enumeration of activated, CD4+ 
cells in immunized animals has revealed significant 
reductions following FK S06 treatment14 . At the same 
time, FK 506 may selectively inhibit the development 
of mature, CD4+ T cells within the thymus and the 
numbers of these cells reaching peripheral lymphoid 
tissue15.36 • 
INFLUENCE OF FK 506 IN AUTOIMMUNE 
DISEASE MODELS 
Uveitis 
Experimental autoimmune uveitis (EAU) is an organ-
specific autoimmune disease of the eye that can be 
induced by immunization with retinal antigens, i.e. 
retinal soluble antigen (S-antigen) or interphotorecep-
tor retinoid-binding protein (IRBP). EAU is believed 
to be T lymphocyte mediated and a good model of 
autoimmune uveitis in humans. The influence of FK 
506 in EAU has been studied extensively in the Lewis 
rat by Mochizuki and his colleagues. FK 506 was 
found to be 10-30 times more potent than CsA in pre-
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venting induction of EAU when administered either 
from 0-5 days or from 7-12 days after S-antigen 
immunization. It appears that FK 506 is effective in 
suppressing on-going immunopathological processes, 
even after the disease has been initiated37 • As with 
CsA, the immunological unresponsiveness induced by 
a 2-week course of FK 506 (days 0-14) was found to 
be specific to the S-antigen. Whilst splenic lympho-
cytes from animals treated with either drug showed 
markedly depressed in vitro responses to S-antigen, 
only FK 506 was found to significantly depress serum 
antibody levels38 • EAU induction, as well as immune 
responses to S-antigen were suppressed long after 
cessation of FK 506 treatmene9• 
It has been reported that spleens of S-antigen 
immunized and FK 506-treated rats contain antigen-
specific T suppressor cells which, when transferred to 
live recipients can inhibit the induction of EAU. 
Moreover, Ts cells from the same donors suppress 
antigen-specific proliferative responses of S-antigen 
primed cells without influencing responses of IRBP-
sensitized cells40• 
Immunohistochemical studies on lymphocytes infil-
trating the ocular lesions in EAU have revealed that 
FK 506 reduces the absolute number of T cells, 
potentiates the recruitment of CD8+ (Tc/s) cells, and 
inhibits both IL-2R expression on T cells and 
expression of MHC class II antigens on ocular resi-
dent cells41 • Further insight into the mode of action of 
FK 506 in uveitis comes from the observation that the 
drug reduces intercellular adhesion molecule (lCAM-
1) expression on both CD4+ lymphocytes and retinal 
pigment epithelial (RPE) cells (candidate antigen pre-
senting cells). FK 506 also inhibits binding of CD4+ 
lymphocytes to RPE cells42• 
In rhesus and cynomolgus monkeys, FK 506 
(0.5 mg/kg/day) administered i.m. for at least 2 weeks 
from 3 weeks after immunization with S-antigen pre-
vented EAU. Antibody titres against S-antigen were 
reduced, whilst S-antigen-induced lymphocyte pro-
liferation in vitro was unchanged or decreased during 
FK 506 treatment43• 
To date, there are no published data concerning 
effects of local (topical or intravitreal) FK 506 admin-
istration in experimental uveitis. 
Arthritis 
Collagen arthritis can be induced readily in many rat 
strains by immunization with homologous or heterol-
ogous native type II collagen emulsified in complete 
Freund's adjuvant (CFA). 
The disease is characterized by the development of 
cellular and humoral responses to type II collagen and 
can be transferred by sensitized spleen and lymph 
node cells and by antibodies to type II collagen. 
Inamura et al.44 reported that administration of FK 
506 to Lewis rats for 12 days following immunization 
suppressed arthritis and inhibited both antibody and 
delayed-type hypersensitivity (DTH) skin tests to type 
II collagen. Failure of the animals to respond to re-
immunization on day 50, but to develop experimental 
allergic encephalomyelitis in response to myelin basic 
protein, suggested the development of long-lasting, 
antigen-specific unresponsiveness44• Studies by Arita 
et al. 45 in Sprague-Dawley rats confirmed the efficacy 
of FK 506 in preventing collagen-induced arthritis; a 
single injection of 10 mg/kg at the time of immuniz-
ation suppressed arthritis completely and almost abol-
ished IgG antibody and DTH responses to type II col-
lagen. They further showed that if withheld until day 
12 or 15 after immunization, the same single high 
dose of FK 506 was effective in suppressing existing 
disease and immune (humoral) responses to type II 
collagen. Moreover, pretreatment of rats with a single 
FK 506 injection (10 mg/kg) (day -7 or -3) reduced 
disease severity and antibody production. 
Similar results concerning the prophylactic effect of 
FK 506 in collagen arthritis have been obtained in 
mice using doses of drug 25 times lower than effect-
ive doses of CSA46 • As with CsA, FK 506 was ineffec-
tive in treatment of established lesions in the mouse. 
Insulin-dependent diabetes 
Spontaneously diabetic BB rats are considered an 
excellent model for type I, insulin-dependent diabetes 
mellitus (IODM). The disease shows genetic predis-
position, abrupt onset of insulin-dependent ketosis-
prone diabetes (60-120 days of age) associated with 
lymphocytic insulitis and virtually complete destruc-
tion of pancreatic P cells. Administration of FK 506 
(2 mg/kg/day) from 30 to 120 days of age prevented 
the development of diabetes in 20/20 BB rats during 
the treatment period. Blood glucose and renal and 
hepatic function tests remained normal whilst histo-
logical examination confirmed the absence of insul-
itis47 • Glucose intolerance, which has been described 
in BB rats given CsA was not observed in this study. 
In non-obese diabetic (NOD) mice, IDDM develops 
spontaneously in about 80% of female mice between 
weeks 12 and 26. The disease is thought to have a 
CD4+ T cell dependent autoimmune pathogenesis. 
Administration of FK 506 (2 mg/kg/48 hr) to female 
NOD mice from weeks 5-20 inhibited both the insul-
itis and the occurrence of diabetes (cumulative inci-
dence up to 40 weeks: 86% in control mice and 23% 
in FK 506-treated animals). These effects were 
accompanied by significant reductions in splenic 
CD4+ and CD8+ T cells compared with untreated con-
trols, suggesting that the suppression of disease 
activity may be linked to inhibition of cell-mediated 
autoimmune reactivity48. 
In both the BB rat and NOD mouse studies, the pre-
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ventive effect of FK 506 in diabetes often outlasted 
the duration of treatment by many weeks or in some 
animals permanently. 
Spontaneous autoimmune lupus disease 
The New Zealand black/white (NZB/W) hybrid mouse 
spontaneously develops non organ-specific, auto-
immune immune complex type disease that resembles 
systemic lupus erythematosus in man. Nephritis and 
proteinuria develop within 2-3 months of age, leading 
to chronic renal failure and 50% mortality by 8-9 
months. Takabayashi et al.49 reported that FK 506 
(2.5 mg/kg, 3 times per week from 12 weeks of age) 
prolonged the lifespan of female NZB/W Fl mice and 
significantly reduced proteinuria. There were, how-
ever. no differences in anti-dsDNA antibody levels or 
IgG subclass distribution between drug-treated ani-
mals and controls. 
The MRL/lpr mouse spontaneously develops glo-
merulonephritis, marked lymphoid hyperplasia, arter-
itis and chronic polyarthritis, with 50% mortality at 
about 5 months. Takabayashi et al.49 reported similar 
effects of FK 506 on survival, proteinuria and anti-
dsDNA antibody levels in MRL/lpr female mice 
(given 2.5 mg/kg FK 506 3 times per week from 8 
weeks old) to those observed in NZB/W Fl hybrids. 
Compared with untreated MRL/lpr controls, minimal 
glomerulonephritis with only mild proliferation of 
endothelial and mesangial cells was noted, whilst 
immunoglobulin and C3 deposits were restricted 
mainly to the mesangia. Using a similar FK 506 treat-
ment protocol, Yamamoto et al. 5o found that inhibition 
of disease activity in MRL/lpr mice was accompanied 
by significant reductions in serum anti-ssDNA and 
anti-ds DNA activities. 
Experimental autoimmune glomerulonephritis 
There are several ways of inducing immune-mediated 
nephritis in experimental animals. Heymann's neph-
ritis is a membranous type of chronic glomerulo-
nephritis with glomerular subepithelial immune 
deposits induced by autologous antibody against renal 
tubular brush border (TBB) antigens. It is induced in 
rats by footpad immunization with TBB antigen in 
FCA. Another type of glomerulonephritis (nephro-
toxic antiserum nephritis or Masugi nephritis) is 
induced by the intravenous injection of (rabbit) anti-
body to rat glomerular basement membrane (GBM). 
Okuba et al.'1 have shown that FK 506 (0.64 mg/kg) 
given for 14 days from the time of TBB immunization 
completely suppresses development of Heymann's 
nephritis. They have also found that FK 506 prevents 
the autologous phase (i.e. production of antibody 
against rabbit gamma globulin fixed on the GBM) of 
nephrotoxic antiserum nephritis. In both models, the 
rats remained tolerant to the immunizing antigens but 
not to other antigens for at least 14 weeks after drug 
withdrawal. The induction of FK 506 of long lasting, 
antigen-specific unresponsiveness is similar to the 
effects of the drug in EAU and collagen-induced 
arthritis (see above). The underlying mechanism(s) 
has not been elucidated but possible explanations 
include clonal deletion or the induction of anti-
idiotypic antibody or antigen-specific suppressor 
cells. 
Glomerulonephritis can also be induced by preim-
munization of rats with normal rabbit IgG and the 
subsequent i. v. injection of rabbit anti-GBM antibody 
(accelerated nephrotoxic serum glomerulonephritis). 
In this model, FK 506 suppresses the autologous 
response to rabbit IgG and reduces substantially, the 
glomerular injury52. 
Autoimmune thyroiditis 
Experimental autoimmune thyroiditis can be induced 
in female PVG/c rats by early thymectomy followed 
by a course of sublethal total body irradiation (TBI). 
This results in progressive, lymphocytic infiltration 
of the thyroid, follicular obliteration and production 
of anti-thyroglobulin. Administration of FK 506 
(2 mg/kg/day) from week 8 after the last dose of TBI 
significantly decreases the disease severity and is 
associated with reversal of the splenic CD4+: CD8+ T 
cell ratio (G. Carrieri, N. Murase, 1. Woo and A.W. 
Thomson, unpublished observations). 
Allergic encephalomyelitis 
Experimental allergic encephalomyelitis (EAE) is 
induced in susceptible rat strains by a single injection 
of myelin basic protein (MBP) in FCA. An acute para-
lytic disease develops within 10-14 days after immun-
ization with features similar to human acute inflam-
matory central nervous system disease. FK 506 
(1 mg/kg 5 days per week for 2 weeks from the time 
of immunization) prevented development of EAE for 
at least 50 days and completely suppressed both anti-
body production and cell-mediated immunity to MBP. 
The effectiveness of the drug, however, was consider-
ably reduced when treatment was delayed until 7 days 
after immunization53 . Recently, it has been observed 
that the adoptive transfer of EAE can be suppressed 
by in vitro treatment of spleen cells with I nM FK 
506, 100-fold lower than the effective concentration 
of CSA54 • 
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Dermatological disorders 
Experience with FK 506 in human autoimmune dis-
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orders is very limited. Nevertheless, both the efficacy 
and therapeutic potential of the drug have been dem-
onstrated in several diseases. The capacity of FK 506 
to clear psoriatic skin lesions was first observed in 
organ transplant recipients, whilst a group of seven 
patients (median follow up time 7 months) with sev-
ere, recalcitrant, chronic plaque psoriasis unrespon-
sive to conventional therapy showed a marked 
reduction (93%) in psoriasis area and severity index 
within 4 weeks of commencement of oral FK 506 
treatment (starting dose 0.3 mg/kg/day)55,56. Psoriatic 
arthritis present in 4 patients also improved markedly 
within this period. Examination of lesional biopsies 
revealed that disease remission was accompanied by 
reduction in dermal and epidermal T cells57. Elev-
ations in serum creatinine were observed after 1-6 
months but responded quickly to dose reduction. FK 
506 did not induce severe hypertension in any of the 
patients and blood glucose, liver enzymes, bilirubin, 
cholesterol and uric acid were maintained within nor-
mal limits. Clinical side effects were minor and 
included nausea, mild tremors, headaches and insom-
nia not necessitating drug withdrawal. FK 506 mono-
therapy has also been used effectively in four patients 
with pyoderma gangrenosum58. Each subject had been 
previously treated unsuccessfully with conventional 
immunosuppressive therapy. Complete healing of the 
skin, as well as remission of the associated non-
dermatological lesions, including perianal fistulae 
(due to Crohn' s disease) in one patient was achieved 
within 6 weeks with no serious side effects. 
Uveitis 
Mochizuki and his colleagues have reported 13 cases 
of refractory uveitis (mean follow up 6 weeks), 
including 12 patients with Behget's disease, in which 
beneficial effects of FK 506 (0.05-0.2 mg/kg/day) i.e. 
improved visual acuity and decreased uveitis were 
achieved in the majority of patients, without serious 
side effects59• 
Nephrotic syndrome 
McCauley et al.60 reported successful treatment of 2 
patients with steroid-resistant nephrotic syndrome 
with FK 506. More recently, the same group61 has 
reported marked and sustained reductions in pro-
teinuria in 6 out of 7 patients with primary glomerulo-
nephritis resistant to all other forms of therapy. Creat-
inine clearance decreased in all patients after starting 
FK 506 but improved upon dose reduction. Disease 
recurrence was prompt in two patients who stopped 
Table 1 Experimental autoimmune diseases suppressed by FK 506. 
Disorder 
Arthritis 
(Type II 
collagen-
induced 
Species 
Rat (Lewis) 
Rat (outbred) 
FK 506 dose 
mg/kg/day 
unless 
specified 
0.32,·b 
2.5" 
Mouse (DBNI) 2.0 
Reference 
Inamura et al.41 
(1988) 
Arita et al.42 
(1990) 
Takagishi et al.43 
(1989) 
Type I 
diabetes 
NOD mouse 2.0 mg/kg/48 hI" Miyagawa et al.45 
(1990) 
BB rat 
Uveoretinitis Rat (Lewis) 
Rhesus & 
cynomolgus 
monkeys 
Thyroiditis Rat (PVG) 
Lupus (SLE) MRL-Ipr/lpr 
1.0' 
os 
2.0' 
Murase et al.44 
(1990) 
Kawashima et 
al." 
(1990) 
Fujino et al.40 
(1990) 
Carrieri et al. 
(1991) 
unpublished 
Yamamoto et al.'7 
(1990) 
NZB/NZW F, 2.5 mg/kg/48 hr" Takabayashi et 
mouse al.46 
Glomerulo- Rat (Wistar) 
nephritis 
(Nephrotoxic Rat (Wistar) 
antiserum 
nephritis) 
Heymann's Rat (Wi star) 
nephritis 
Allergic Rat (Lewis) 
encephalomye 
litis 
"Suppresses induction of disease. 
0.3 mgh 
0.64 
0.64" 
1.0' 
bPartially effective during efferent phase of response. 
"'On day of immunization. 
dEffective only in induction phase. 
eAdministcred from 3 weeks after immunization. 
'Administered for 3 we~ks following induction of disease. 
I'Administered from 8 weeks of age. 
hFrom time of immunization. 
'Administered 5 days per week after immunization. 
(1989) 
Hara et al.49 
(1990) 
Okuba et al.'8 
(1990) 
Okuba etal." 
(1990) 
Inamura et al.50 
(1988) 
taking FK 506 temporarily, but their nephrotic syn-
drome was controlled rapidly following reinstatement 
of FK 506 therapy. Patients with transplant-related 
nephrotic syndrome without chronic rejection were 
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Table 2 FK 506 in human autoimmune disease. 
FDA-Apprm'cd Protocols University of Pittsburgh 
Renal disease 
Nephrotic syndrome 
Liver disease 
Primary biliary cirrhosis 
Connective tissue disorder 
Systemic sclerosis 
Skin diseases 
Psoriasis 
Pyoderma gangrenosum 
Recent onset type [ diabetes 
Ophthalmic disorders 
Uveitis 
Scleritis 
Cicatricial pemphigoid 
Inflammatory bowel disease 
Crohn's disease 
Crohn's colitis 
Ulcerative colitis 
Other autoimmune disease protocols. FDA approval of which is pending. include chronic 
active hepatitis, rheumatoid arthritis, systemic lupus erythematos·us, polymyositis-
polydcnnutomyositis, sprue (celiac disease), multiple sclerosis. Beh~elDs syndrome, 
systemic vasculilidies. 
less benefited from FK 506, the majority failing to 
respond but with notable exceptions. 
The efficacy and safety of FK 506 in these and a 
variety of other human autoimmune disorders, includ-
ing recent onset type I diabetes and inflammatory 
bowel diseases are presently being evaluated at the 
University of Pittsburgh Medical Centre. 
CONCLUSIONS 
Although it is too early to draw firm conclusions 
about the value of FK 506 in human autoimmune dis-
ease from the limited clinical investigations which 
have been undertaken to date, preliminary obser-
vations are encouraging. There is no doubt that FK 
506 is at least as efficacious an immunosuppressant as 
CsA. Its capacity (unlike CsA) to reverse allograft 
rejection suggests that it may be more broadly effect-
ive than CsA in autoimmune disease and may be use-
ful in patients unresponsive to high dose steroids 
and/or other forms of immunosuppressive therapy. 
Further studies must include dose range and long term 
evaluation of FK 506 therapy. Because FK 506 aug-
ments hepatic repair and regeneration, it may prove 
especially valuable in patients with autoimmune liver 
disease. Although FK 506 and CsA share several 
potential side effects, including nephrotoxicity, FK 
506 is less apt to induce hypertension and does not 
cause gingival hyperplasia or hirsutism at all. 
Amongst the beneficiaries of FK 506 therapy have 
been a high proportion of paediatric heart transplant 
recipients62 in whom steroids have never been used 
and children with nephrotic syndrome, in which prior 
high dose steroids have been discontinued60• The 
inclusion of FK 506 on the limited list of immunosup-
pressive drugs available for human autoimmune dis-
ease therapy appears justifiable. 
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